Antitrust - Amgen - Carefirst's litigation over alleged monopoly over Enbrel (US)

Track this case file

CareFirst filed a US antitrust case against Amgen, accusing the company of unlawfully delaying competition for its drug Enbrel, which is used to treat inflammatory diseases. According to the complaint, Amgen’s Enbrel profits for at least the last five years are attributable to its unlawful campaign to buttress and entrench what was once a legitimate, patent-protected Enbrel monopoly by preventing competition from biosimilar versions of the drug.

To add details to this portfolio regarding legal or economic representatives, please contact editors@mlex.com

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login